Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-04-05
2011-04-05
Aeder, Sean E (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07919261
ABSTRACT:
The invention disclosed herein describes novel biomarkers useful for risk assessment, screening, prognosis and selection and monitoring of therapy for HDAC mediated cell proliferative disorders. In particular, the invention provides the identities of three particular proteins whose expression patterns are strongly predictive of a particular patient's treatment outcome, e.g., non-responsiveness to SAHA. The expression profile, or pattern, whether embodied in nucleic acid expression, protein expression, or other expression formats will find use in identifying and selecting patients afflicted with a particular HDAC mediated cancer who are likely to be non-responsive to SAHA-based therapy and thus candidates for other treatments.
REFERENCES:
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Frank et al (Cancer Treatment and Research, 2003, 115: 267-291).
Sommer VH et al., Leukemia, vol. 18, pp. 1288-1295 (2004), “In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3”.
Kari, L et al., The Journal of Experimental Medicine, vol. 197, No. 11, pp. 1477-1488 (2003), “Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma”.
Alas, S et al., Clinical Cancer Research, vol. 9, pp. 316-326 (2003), “Inhibition of constitutive STAT3 activity sensitizes resistant non-hodgkin's lumphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis”.
Ikuta, K et al., Oncology Reports, vol. 13, pp. 217-222 (2005), “Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells”.
Khoury, JD et al., Clinical Cancer Research, vol. 9, pp. 3692-3699 (2003), “Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK− anaplastic large cell lymphoma”.
Mitchell, TJ et al., Immunology, vol. 114, pp. 301-312 (2005), “Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas”.
Roberts, D et al., British Journal of Cancer, vol. 92, pp. 1149-1158 (2005), “Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells”.
Yu, H et al., Nature Reviews Cancer, vol. 4, pp. 97-105 (2004), “The STATS of cancer—new molecular targets come of age”.
George SR et al., Nature Reviews Drug Discovery, vol. 1, pp. 808-820 (2002), “G-protein-coupled receptor oligomerization and its potential for drug discovery”.
Mellado, M et al., Annual Review of Immunology, vol. 19, pp. 397-421 (2001), “Chemokine signaling and functional responses: The role of receptor dimerization and TK pathway activation”.
Schlessinger, J, Cell, vol. 103, pp. 211-225 (2000), “Cell signaling by receptor tyrosine kinases”.
Yarden, Y, European Journal of Cancer, vol. 37, pp. S3-S8 (2001), “The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities”.
Herbst, RS et al., Cancer, vol. 94, No. 5, pp. 1593-1611 (2002), “Monoclonal antibodies to target epidermal growth factor receptor-positive tumors”.
Yarden, Y et al., Nature Reviews Molecular Cell Biology, vol. 2, pp. 127-137 (2001), “Untangling the ErbB signalling network”.
McCormick, F, Trends in Cell Biology, vol. 9, No. 12, pp. M53-M56 (1999), “Signalling networks that cause cancer”.
Blume-Jensen, P et al., Nature, vol. 411, pp. 355-365 (2001), “Oncogenic kinase signaling”.
Davie, JR, Current Opinion in Genetics & Development, vol. 8, pp. 173-178 (1998), “Covalent modifications of histones: expression from chromatin templates”.
Kouzarides, T, Current Opinion in Genetics & Development, vol. 9, pp. 40-48 (1999), “Histone acetylases and deacetylases in cell proliferation”.
Strahl, BD et al., Nature, vol. 403, pp. 41-45 (2000), “The language of covalent histone modifications”.
Ng, HH et al., Trends in Biolochemical Sciences, vol. 25, pp. 121-126 (2000), “Histone deacetylases: silencers for hire”.
Gray, SG et al., Experimental Cell Research, vol. 262, pp. 75-83 (2001), “The human histone deacetylase family”.
Petricoin, EF et al., Nature Reviews Drug Discovery, vol. 1, pp. 683-695 (2002), “Clinical proteomics: Translating benchside promise into bedside reality”.
Sidransky, D, Nature Reviews Cancer, vol. 2, pp. 210-219 (2002), “Emerging molecular markers of cancer”.
Wargovich, MJ et al., Cancer Epidemiology, Biomarkers & Prevention, vol. 5, pp. 355-360 (1996), “Aberrant crypts as a biomarker for colon cancer: Evaluation of potential chemopreventive agents int he rat”.
deVere White, RW et al., Oncology, vol. 12, No. 12, pp. 1717-1726 (1998), “Predicting prognosis in patients with superficial bladder cancer”.
Stein JP et al., The Journal of Urology, vol. 160, pp. 645-659 (1998), “Prognostic markers in bladder cancer: A comtemporary review of the literature”.
Cook, AM et al., Proceedings of the American Society of Clinical Oncology, vol. 17, abstract 1199 (1998), “The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer”.
van Haaften-Day, C et al., Cancer, vol. 92, No. 11, pp. 2637-2644 (2001), “OVX1, Macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma, a critical appraisal”.
Sambrook, J et al., Molecular Cloning: A Laboratory Manual, vol. I and II (1989).
Mullis KB et al., Methods in Enzymology, vol. 155, pp. 335-350 (1987), “Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction”.
Karlin, S et al., Proceedings of the National Academy of Sciences, vol. 87, pp. 2264-2268 (1990), “Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes”.
Karlin, S et al., Proceedings of the National Academy of Sciences, vol. 90, pp. 5873-5877 (1993), “Applications and statistics for multiple high-scoring segments in molecular sequences”.
Myers, EW et al., CABIOS, vol. 4, No. 1, pp. 11-17 (1988), “Optimal alignments in linear space”.
Bird, RE et al., Science, vol. 242, pp. 423-426 (1988), “Single-chain antigen-binding proteins”.
Huston, JS et al., Proceedings of the National Academy of Sciences, vol. 85, pp. 5879-5883 (1988), “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli”.
Frank, DA, Cancer Treatment and Research, vol. 115, pp. 267-291 (2003), “STAT signaling in cancer: insights into pathogenesis and treatment strategies in signal transduction in cancer”.
Bromberg, J., “Stat proteins and oncogenesis”, Journal of Clinical Investigation, 109(9):1139-1142; American Socitey for Clinical Investigation; XP002269665, ISSN:0021-9738, (May 2002).
Klampfer, L. et al., “Requirement for Histone Deacetylase Activity for Signaling by STAT1”, Journal of Biological Chemistry, 279(29):30358-30368;XP009127861, ISSN: 0021-9258, (Jul. 16, 2004).
Sun, W. H., et al., “Interferon-alpha Resistance in a Cutaneous T-Cell Lymphoma Cell Line is Associated with Lack of STAT1 Expression”, Blood 91(2):570-576; XP009127766; ISSN: 0006-4971, (Jan. 15, 1998).
Zhang, C., et al., “Selective Induction of Apoptosis by Histone Deacetylase Inhibitor SAHA in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic Action”, The Journal of Investigative Dermatology, 125(5):1045-1052;XP002563294, ISSN: 0022-202X (Nov. 2005).
Fantin Valeria R.
Loboda Andrey
Pierce Jacqueline W.
Aeder Sean E
Merck Sharp & Dohme Corp.
Muthard David A.
Su Li
LandOfFree
Methods for predicting treatment response based on the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for predicting treatment response based on the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for predicting treatment response based on the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2650938